To compare the safety and antidepressant efficacy of paroxetine, imipramine, and placebo, data from six centres using the same protocol were pooled. A double-blind parallel-group design was used, with therapy lasting six weeks. From week 2 onwards, both the 240 paroxetine-treated and the 237 imipramine-treated patients were significantly different from the 240 placebo-treated patients, but no different from each other. Side-effects with paroxetine were less likely to lead to drop-out than with imipramine. Paroxetine had a possible earlier antidepressant effect than imipramine, and a possible earlier beneficial effect on anxiety symptoms associated with depression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1192/bjp.159.3.394 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Desvenlafaxine with mindfulness-based cognitive therapy reduces Hamilton anxiety scores compared to escitalopram with mindfulness-based cognitive therapy in treatment-resistant generalized anxiety disorder.
Pharmacol Biochem Behav
January 2025
Department of Pharmacology, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Tamilnadu, India. Electronic address:
Background: This study aims to assess the effectiveness of low-dose Escitalopram (10 mg) or low-dose Desvenlafaxine (25 mg) combined with mindfulness-based cognitive therapy (MBCT) in addressing challenges in treating generalized anxiety disorder (GAD), particularly in patients resistant to conventional therapies.
Methods: A prospective cohort study was conducted with individuals diagnosed with treatment-resistant GAD. group A included patients unresponsive to citalopram, imipramine, paroxetine, and sertraline, who were then treated with low-dose Escitalopram (10 mg) combined with MBCT.
Effect of antidepressants on ejaculation dysfunction in patients with depression and anxiety: A systematic review and network meta-analysis.
Andrology
September 2024
Department of Urology, Tianjin Medical University General Hospital, Tianjin, China.
Introduction: Antidepressants may lead to a series of sexual adverse effects (SAEs), among which ejaculation dysfunction (EjD) is often overlooked by clinicians. The purpose of the present network meta-analysis was to assist drug adjustment by comparing and ranking the incidence of EjD among various antidepressants.
Methods: Relevant studies were retrieved from PubMed, Embase, Scopus, Web of Science, ClinicalTrials.
Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.
Lancet Psychiatry
July 2024
Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne, 50937 Cologne, Germany. Electronic address:
Background: Antidepressant discontinuation symptoms are becoming an increasingly important part of clinical practice, but the incidence of antidepressant discontinuation symptoms has not been quantified. An estimate of antidepressant discontinuation symptoms incidence could inform patients and clinicians in the discontinuation of treatment, and provide useful information to researchers in antidepressant treatments. We aimed to assess the incidence of antidepressant discontinuation symptoms in patients discontinuing both antidepressants and placebo in the published literature.
View Article and Find Full Text PDFChallenges in the treatment of dysthymia: a narrative review.
Expert Rev Neurother
July 2024
Institute of Psychiatry, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Article Synopsis
- Dysthymia, a chronic and less severe form of depression, leads to significant impairments but has received less research focus than major depressive disorder (MDD).
- The authors conducted a thorough review of treatment options for dysthymia by analyzing original studies retrieved from PubMed, specifically targeting samples diagnosed according to established DSM criteria.
- Several antidepressants, like sertraline and paroxetine, showed benefits compared to placebo, but findings on psychotherapy are inconclusive due to limited studies and various methodological issues such as small sample sizes and lack of blinding.
Comparative responses to 17 different antidepressants in major depressive disorder: Results from a 2-year long-term nation-wide population-based study emulating a randomized trial.
Acta Psychiatr Scand
May 2024
Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
Background: Long-term studies comparing nonresponse to antidepressants for major depressive disorder (MDD) are lacking.
Aims: To present systematic population-based nation-wide register data on comparative 2-year non-response within six antidepressant drug classes and 17 different antidepressants in patients with MDD.
Method: The study included all 106,920 patients in Denmark with a first main index diagnosis of MDD at a psychiatric hospital inpatient or outpatient contact and who subsequently had a purchase of an antidepressant in the period from 1995 to 2018.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!